Observational studyDiving and hyperbaric medicine2025
Functional outcome and quality of life after iatrogenic cerebral air embolism treated with hyperbaric oxygen: a prospective cohort study.
Observational study in Diving and hyperbaric medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Iatrogenic cerebral air embolism (CAE) is an uncommon, potentially fatal condition characterised by accidental introduction of air into the circulation during invasive procedures. Prompt recognition and treatment with hyperbaric oxygen therapy (HBOT) are required. Data on long-term functional outcome and specifically quality of life (QoL) in patients experiencing CAE are limited. Methods: This prospective, single-centre, observational cohort study examined patients with iatrogenic CAE who were treated with HBOT. Patient characteristics, clinical severity scores and treatment details were recorded. The primary outcomes of the study were the Glasgow Outcome Scale (GOS) score at discharge and six months, and QoL measured by the World Health Organization quality of life brief version at six months. Results: A total of 22 patients were included, with 14 patients (64%) having arterial CAE, five (23%) retrograde venous CAE, and the remaining three having either both (n = 1) or unknown (n = 2) forms of CAE. Median time-to-HBOT was seven hours [IQR 5-10]. The overall mortality rate was 23% (n = 5), eight of 22 patients achieving full recovery (GOS 5) at six months, and another six patients having moderate disability (GOS 4) at six months. Nine of 17 survivors (53%) reported a decline in QoL compared to their pre-incident status. Outcome in patients with retrograde venous CAE seemed to be better, and outcome in patients with CAE following neuroangiographic procedures for stroke or subarachnoid haemorrhage seemed to be worse, compared to the remainder of patients. Conclusions: Iatrogenic CAE is associated with substantial morbidity and mortality, with only a third of patients in our cohort achieving good functional recovery. Over half of survivors in this cohort self-reported reduced QoL as compared to their situation before the CAE incident.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.